Company: VCYT
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001384101-25-000051
Chunk: 47

Company: VERACYTE, INC.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 47
---
1 to 2012, and Senior Manager, Investor Relations at Life Technologies, Inc., a biotechnology company, from 2009 to 2010. She also previously held positions with Bank of America, a financial services company, and Millennium Pharmaceuticals, a biopharmaceutical company. Ms. Chambers previously served on the board of Inari Medical, Inc. from 2021 until its acquisition by Stryker in February 2025. Ms. Chambers holds a B.S. from John Carroll University and an M.B.A. from The S.C. Johnson Graduate School of Management, Cornell University. |
| REBECCA CHAMBERS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Age:47                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
 Position(s) at Veracyte:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
 Chief Financial Officer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
 Position(s) Held Since:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
 July 2021                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

#### Veracyte2025 Proxy Statement43

#### Executive Officers
| Phillip Febbo, M.D., has served as our Chief Scientific Officer and Chief Medical Officer since October 2023. Previously, Dr. Febbo was the Chief Medical Officer at Illumina, Inc. from 2018 to 2023. Immediately before joining Illumina, Inc., Dr. Febbo served as CMO of Genomic Health, Inc. from 2013 to 2018. Earlier in his career, Dr. Febbo was a Professor of Medicine and Urology at the University of California, San Francisco. Dr. Febbo currently serves on the board of the Regan Udall Foundation for the FDA. Dr. Febbo previously served on the board of the American College of Medical Genetics and Genomics Foundation from 2018 to 2023 and as a Director on the board of Varian Medical Systems, Inc. from 2019 to 2021. Dr. Febbo holds a B.A. in Biology from Dartmouth College and an M.D. from UCSF. He completed his internal medicine residency at the Brigham and Women’s Hospital and his fellowship in oncology at the Dana-Farber Cancer Institute. While an Attending Physician in the Genitourinary Oncology Center at Dana-Farber and Instructor at Harvard Medical School, he spent five years as a post-doctoral fellow in Dr. Todd Golub